BenevolentAI société anonyme operates as a clinical-stage AI-enabled drug discovery company. The company's BenevolentAI platform powers a pipeline of approximately 20 drug programs. BenevolentAI société anonyme was formerly known as BenevolentAI Limited and changed its name to BenevolentAI société anonyme on April 22, 2022. The company is headquartered in London, United Kingdom.